AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21606858 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-dependent recovery time (FT80)
Number of subjects: 21
Study 21606858 — intervention group
Group type: COMPARATOR
Intervention: Control group (2-minute recovery)
Number of subjects: 21
Study 18031520 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg bid
Number of subjects: 4600
Study 18031520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4600
Study 16525572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran plus ASA (36 mg and 72 mg)
Number of subjects: 62
Study 16525572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran plus ASA (72 mg)
Number of subjects: 62
Study 16525572 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus ASA
Number of subjects: 62
Study 14514744 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly Qa plus standard surveillance (dynamic venous pressure and physical examination)
Number of subjects: 112
Study 14514744 — intervention group
Group type: COMPARATOR
Intervention: Standard surveillance alone
Number of subjects: 112
Study 14514744 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (monthly Qa plus standard surveillance)
Number of subjects: 112
Study 14514744 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard surveillance alone)
Number of subjects: 112
Study 14514744 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) therapy at baseline
Number of subjects: 112
Study 14514744 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline Qa
Number of subjects: 112
Study 14514744 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer interval since graft insertion
Number of subjects: 112
Study 11068300 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Stimulation (FMS)
Number of subjects: 32
Study 11068300 — intervention group
Group type: COMPARATOR
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 32
Study 9048387 — intervention group
Group type: COMPARATOR
Intervention: General endotracheal anesthesia alone (Group I)
Number of subjects: 195
Study 9048387 — intervention group
Group type: EXPERIMENTAL
Intervention: General endotracheal anesthesia with epidural augmentation (Group II)
Number of subjects: 195
Study 9048387 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia only (Group III)
Number of subjects: 195
Study 7861794 — intervention group
Group type: EXPERIMENTAL
Intervention: DUI treatment program
Number of subjects: 7316
Study 2800889 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin (IMP)
Number of subjects: 83
Study 2800889 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin plus amikacin (PA)
Number of subjects: 83
Study 998633 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered intravenous solutions
Number of subjects: 49
Study 998633 — intervention group
Group type: COMPARATOR
Intervention: Unfiltered intravenous solutions (Control)
Number of subjects: 49
Study 31999606 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil inhaler (AromaStick®)
Number of subjects: 0
Study 30134143 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene intervention in kindergartens only
Number of subjects: 8275
Study 30134143 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene intervention in both kindergartens and families
Number of subjects: 8275
Study 30134143 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 8275
Study 28314326 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 864
Study 28314326 — intervention group
Group type: COMPARATOR
Intervention: No maintenance therapy
Number of subjects: 864
Study 28314326 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy (with maintenance)
Number of subjects: 864
Study 25676422 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (IM)
Number of subjects: 1503
Study 25676422 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg
Number of subjects: 1503
Study 25676422 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg and IM 400 mg plus interferon α (IFN)
Number of subjects: 1503
Study 24390040 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose odorant application
Number of subjects: 27
Study 24390040 — intervention group
Group type: COMPARATOR
Intervention: Placebo application
Number of subjects: 27
Study 22956840 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinship-related social scenarios evocative of affiliative emotion
Number of subjects: 0
Study 22956840 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MRI
Number of subjects: 0
Study 19740732 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Skill Acquisition Program (ASAP) rehabilitation for 3 weeks
Number of subjects: 5
Study 17969467 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alcohol (0.03% BAC) after extended wakefulness (18-21 hours awake)
Number of subjects: 19
Study 17969467 — intervention group
Group type: COMPARATOR
Intervention: No alcohol after extended wakefulness (18-21 hours awake)
Number of subjects: 19
Study 17969467 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alcohol (0.03% BAC) in a non-sleep-deprived state
Number of subjects: 19
Study 17969467 — intervention group
Group type: COMPARATOR
Intervention: High-dose alcohol (0.05% BAC) in a rested state
Number of subjects: 19
Study 15155300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal midazolam 2 mg, fentanyl 10 micro g
Number of subjects: 30
Study 15155300 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 10 micro g
Number of subjects: 30
Study 15155300 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal midazolam alone
Number of subjects: 30
Study 15155300 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intrathecal midazolam and fentanyl
Number of subjects: 30
Study 15155300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal midazolam and fentanyl
Number of subjects: 30
Study 11446941 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring (group B)
Number of subjects: 40
Study 11446941 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring (group A)
Number of subjects: 40
Study 9174307 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled propofol sedation (PCS) combined with a basal infusion of propofol (n = 15)
Number of subjects: 30
Study 9174307 — intervention group
Group type: COMPARATOR
Intervention: Neurolept analgesia using an initial bolus dose of fentanyl (0.7 microg/kg) and droperidol (0.04 mg/kg) followed by a fentanyl infusion (n = 15)
Number of subjects: 30
Study 9174307 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled propofol sedation (PCS)
Number of subjects: 30
Study 9174307 — intervention group
Group type: COMPARATOR
Intervention: Neurolept analgesia
Number of subjects: 30
Study 1532586 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen treatment (oral ethinylestradiol, 150 micrograms daily + intramuscular polyestradiol phosphate, 80 mg/mo)
Number of subjects: 31
Study 1532586 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 31
Study 3084975 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric consultation and management suggestions to primary physicians
Number of subjects: 38
Study 3084975 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychiatric consultation initially)
Number of subjects: 38
Study 3084975 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric consultation after crossover from control
Number of subjects: 38
Study 30395180 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-step hand hygiene technique
Number of subjects: 2923
Study 30395180 — intervention group
Group type: COMPARATOR
Intervention: 6-step hand hygiene technique
Number of subjects: 2923
Study 29331663 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin (40 mg)
Number of subjects: 121
Study 29331663 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (200 mg/M2)
Number of subjects: 121
Study 26769788 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐assessed postoperative recovery follow‐up daily for 14 days via smartphone app including the Swedish web‐version of Quality of Recovery (SwQoR)
Number of subjects: 1000
Study 26769788 — intervention group
Group type: COMPARATOR
Intervention: standard care (no follow-up)
Number of subjects: 1000
Study 24730757 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward treadmill walking
Number of subjects: 88
Study 24730757 — intervention group
Group type: COMPARATOR
Intervention: Forward treadmill walking
Number of subjects: 88
Study 22257543 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐MPS 1,440 mg/d with reduced tacrolimus (n = 46)
Number of subjects: 94
Study 22257543 — intervention group
Group type: COMPARATOR
Intervention: EC‐MPS 720 mg/d with unchanged tacrolimus (n = 48)
Number of subjects: 94
Study 22257543 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐MPS 1,440 mg/d
Number of subjects: 94
Study 22257543 — intervention group
Group type: COMPARATOR
Intervention: EC‐MPS 720 mg/d
Number of subjects: 94
Study 20682157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung hyperinflation maneuver (LHM) using bilevel positive pressure (BIPAP) with expiratory pressure of 20 cmH(2)O and inspiratory pressure of 20 cmH(2)O for 1 to 2 minutes
Number of subjects: 20
Study 20682157 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 20
Study 20682157 — intervention group
Group type: EXPERIMENTAL
Intervention: LHM and Control Group
Number of subjects: 20
Study 17391791 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated CFRT (74Gy/37f) with neo-adjuvant androgen suppression
Number of subjects: 862
Study 17391791 — intervention group
Group type: COMPARATOR
Intervention: Standard CFRT (64Gy/32f) with neo-adjuvant androgen suppression
Number of subjects: 862
Study 17391791 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Escalated and Standard CFRT)
Number of subjects: 862
Study 15811735 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetazolamide 500 mg 1 hour preoperatively followed by 250 mg every 6 hours
Number of subjects: 52
Study 15811735 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical brinzolamide 1% 1 drop every 12 hours starting immediately after speculum removal
Number of subjects: 52
Study 15811735 — intervention group
Group type: COMPARATOR
Intervention: No ocular hypotensive medication (Control group)
Number of subjects: 52
Study 11966940 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulation CLOtest
Number of subjects: 335
Study 11966940 — intervention group
Group type: COMPARATOR
Intervention: Standard CLOtest
Number of subjects: 335
Study 9790625 — intervention group
Group type: EXPERIMENTAL
Intervention: Releasable sutures
Number of subjects: 30
Study 9790625 — intervention group
Group type: COMPARATOR
Intervention: Conventional interrupted sutures
Number of subjects: 30
Study 7620694 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagimid 500 tablets (500 mg metronidazole)
Number of subjects: 16
Study 7620694 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagimid vaginal tablets (100 mg metronidazole)
Number of subjects: 16
Study 2148221 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 476
Study 2148221 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 476
Study 2148221 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 476
Study 7399805 — intervention group
Group type: EXPERIMENTAL
Intervention: Husband participation in all treatment sessions
Number of subjects: 37
Study 7399805 — intervention group
Group type: EXPERIMENTAL
Intervention: Husband participation in the first four sessions
Number of subjects: 37
Study 7399805 — intervention group
Group type: COMPARATOR
Intervention: No husband involvement
Number of subjects: 37
Study 31380563 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine xenograft
Number of subjects: 44
Study 31380563 — intervention group
Group type: COMPARATOR
Intervention: Porcine xenograft
Number of subjects: 44
Study 31084572 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual interviews
Number of subjects: 60
Study 31084572 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-only interviews
Number of subjects: 60
Study 31084572 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated sentences
Number of subjects: 60
Study 31084572 — intervention group
Group type: COMPARATOR
Intervention: Undegraded isolated sentences (control)
Number of subjects: 60
Study 28989278 — intervention group
Group type: EXPERIMENTAL
Intervention: WB‐EMS and protein supplementation (WB‐EMS&P)
Number of subjects: 100
Study 28989278 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated protein supplementation
Number of subjects: 100
Study 28989278 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control
Number of subjects: 100
Study 28989278 — intervention group
Group type: EXPERIMENTAL
Intervention: WB‐EMS
Number of subjects: 100
Study 26476467 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Number of subjects: 331
Study 26476467 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Number of subjects: 331
Study 23322527 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (Risperidone tablet; Dr. Reddy's Laboratories Ltd.)
Number of subjects: 24
Study 23322527 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (Risperdal(®) tablet; Xian‐Janssen Pharmaceutical Ltd.)
Number of subjects: 24
Study 23322527 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study 21262278 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration in a laboratory experiment
Number of subjects: 155
Study 21262278 — intervention group
Group type: COMPARATOR
Intervention: Non-Alcohol Condition
Number of subjects: 155
Study 21262278 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Alcohol Level
Number of subjects: 155
Study 19010571 — intervention group
Group type: EXPERIMENTAL
Intervention: High-polyunsaturated fatty acids from walnuts
Number of subjects: 29
Study 19010571 — intervention group
Group type: EXPERIMENTAL
Intervention: High-monounsaturated fatty acids from olive oil
Number of subjects: 29
Study 19010571 — intervention group
Group type: COMPARATOR
Intervention: High-saturated fatty acids from fat-rich dairy products
Number of subjects: 29
Study 19010571 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat oxidation rates after unsaturated fatty acids meals
Number of subjects: 29
Study 19010571 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat oxidation rates after high-saturated fatty acid meal
Number of subjects: 29
Study 19010571 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial respiratory quotient, protein and carbohydrate oxidation, and satiety measures
Number of subjects: 29
Study 17879021 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (4 mg bolus injection followed by 8 mg/h infusion for 24 h)
Number of subjects: 62
Study 15566926 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 30
Study 15566926 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-progestin replacement therapy
Number of subjects: 30
Study 15566926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11565068 — intervention group
Group type: EXPERIMENTAL
Intervention: piperacillin‐tazobactam plus amikacin (7.5 mg/kg twice daily intravenously)
Number of subjects: 760
Study 11565068 — intervention group
Group type: COMPARATOR
Intervention: piperacillin‐tazobactam plus placebo
Number of subjects: 760
Study 9767221 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal pulse oximetry
Number of subjects: 100
Study 9767221 — intervention group
Group type: COMPARATOR
Intervention: Cardiotocography only
Number of subjects: 100
Study 8152772 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.01% mitomycin C for 5 days
Number of subjects: 75
Study 8152772 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.02% mitomycin C for 5 days
Number of subjects: 75
Study 8152772 — intervention group
Group type: COMPARATOR
Intervention: 1200 rad beta‐irradiation
Number of subjects: 75
Study 3134560 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-liter prepackaged enteral diet delivery system (2000 kcal, 12 g N)
Number of subjects: 40
Study 3134560 — intervention group
Group type: COMPARATOR
Intervention: 1-liter rigid plastic containers filled with cans of Clinifeed 400
Number of subjects: 40
Study 30221457 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% of usual insulin degludec (IDeg) dose
Number of subjects: 9
Study 30221457 — intervention group
Group type: COMPARATOR
Intervention: 100% of usual insulin degludec (IDeg) dose
Number of subjects: 9
Study 28600398 — intervention group
Group type: EXPERIMENTAL
Intervention: plasma mF
Number of subjects: 924
Study 28600398 — intervention group
Group type: EXPERIMENTAL
Intervention: plasma UFA
Number of subjects: 924
Study 26403827 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) for harmful alcohol consumption (AUDIT ≥ 8)
Number of subjects: 73
Study 26403827 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 73
Study 23963821 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical oophorectomy plus tamoxifen therapy
Number of subjects: 270
Study 20498606 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia with dexmedetomidine (LAD)
Number of subjects: 60
Study 20498606 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 60
Study 19080698 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor and levofloxacin based triple therapy
Number of subjects: 1926
Study 16193302 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 kg tension
Number of subjects: 48
Study 16193302 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 kg tension
Number of subjects: 48
Study 16193302 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 kg tension
Number of subjects: 48
Study 16193302 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific tension mentioned)
Number of subjects: 48
Study 12496537 — intervention group
Group type: EXPERIMENTAL
Intervention: GLY-GLN (0.5 g/kg/24 h)
Number of subjects: 45
Study 12496537 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-GLN (0.5 g/kg/24 h)
Number of subjects: 45
Study 12496537 — intervention group
Group type: COMPARATOR
Intervention: Vamin (GLN-free amino acid solution; control group)
Number of subjects: 45
Study 11040017 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment
Number of subjects: 113
Study 11040017 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 113
Study 8899661 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Muscle Testing (MMT)
Number of subjects: 20
Study 8899661 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal Voluntary Isometric Contraction (MVIC)
Number of subjects: 20
Study 8899661 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS Score
Number of subjects: 20
Study 1642145 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight training
Number of subjects: 31
Study 1642145 — intervention group
Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 31
Study 1642145 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 31
Study 6200411 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxypertine
Number of subjects: 12
Study 6200411 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine pamoate
Number of subjects: 12
Study 6200411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31843840 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal occupational rehabilitation programme ('Beyond Cancer')
Number of subjects: 0
Study 31843840 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (historical)
Number of subjects: 0
Study 29122185 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone width of 67 mm
Number of subjects: 20
Study 29122185 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone width of 70 mm
Number of subjects: 20
Study 29122185 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone width of 72 mm
Number of subjects: 20
Study 29122185 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone width of 74 mm
Number of subjects: 20
Study 29122185 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottom bezel level of 2.5 mm
Number of subjects: 20
Study 29122185 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottom bezel level of 5 mm
Number of subjects: 20
Study 29122185 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottom bezel level of 7.5 mm
Number of subjects: 20
Study 29122185 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottom bezel level of 10 mm
Number of subjects: 20
Study 29122185 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottom bezel level of 12.5 mm
Number of subjects: 20
Study 26611433 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based lifestyle intervention (GLI) offered by the YMCA, participation encouraged but not required.
Number of subjects: 331
Study 26611433 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 331
Study 25172519 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 22078129 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10-mg ODT
Number of subjects: 0
Study 22078129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20619137 — intervention group
Group type: EXPERIMENTAL
Intervention: Liangxue Jiedu Huoxue Decoction
Number of subjects: 100
Study 20619137 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (Control)
Number of subjects: 100
Study 18005423 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and Activation Programme (EAP) as an addition to usual care (UC)
Number of subjects: 0
Study 18005423 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) only
Number of subjects: 0
Study 16099694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 54
Study 16099694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 12145055 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.2 mg/kg injected over 10 s
Number of subjects: 206